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j ourna l homepage: www.eb iomed ic ine.comEditorialBanning Psychoactive Substances: A Slippery SlopeOnMay 28, 2015, the Psychoactive Substances Bill was introduced in
the UK House of Lords. Ostensibly meant to curtail so-called “legal
highs” — newly-synthesized chemical intoxicants that are not covered
by current drug laws— the bill would impose a blanket ban on “any sub-
stance that […] affects the person's mental functioning or emotional
state”.While the bill's objective of preventing personal injury and public
harm is noble, it and similar laws in other nations could have unintend-
ed consequences, including hindrance of an already ailing psychiatric
research and drug development pipeline.
The prominence of new psychoactive substances (NPSs) has risen
over the past two decades, on the backs of clever chemists, marketers,
and internet entrepreneurs. Many NPSs are derivatives or analogs of
other, often illegal, psychoactive compounds. To circumvent the United
Nations' 1971 Convention on Psychotropic Substances, which inﬂu-
enced many domestic policies, NPSs are sold at shops as not for
human consumption under the guise of plant food, bath salts, and in-
cense, complete with appealing packaging and names. A proliﬁc inter-
net drug trade has also contributed to the emergence of roughly one
NPSperweek since the late 2000s. Keepingpacewith theNPS industry's
agility imposes serious burden on the legal system.
Regulation of NPSs is necessary. Daily, they harm users who are un-
aware of, or cannot predict, how an untested drug will affect their bod-
ies. Mimicking narcotics like cocaine, opiates, amphetamines, and
cannabis, NPSs have been known to cause hypertension, heart palpita-
tions, seizures, blindness, Parkinsonism, seizures, and death. Laws like
the Psychoactive Substances Bill aim to disrupt manufacturing and dis-
tribution of NPSs, preventing them from falling into the public's hands.
In the real world, though, drug law repercussions on public interests are
hard to predict.
These lawswould also impact the research community. For example,
under the US Drug Enforcement Agency's scheduling system, any drug
that has no currently accepted medical use — such as LSD (acid),
MDMA (ecstasy), and psilocybin (mushrooms) — falls under Schedule
I. Obtaining a license to perform research using these drugs requires
considerablemoney and time, not tomention institution-level ethics re-
view, dissuadingmany scientists from the bother of research on psycho-
active substances. In one example, the burgeoning ﬁeld of LSD-assisted
psychotherapy all but ended in the 1970s when new laws made the
drug nearly impossible for researchers to obtain.
The contradictions among laws and government-funded research
policies have left many scientists confused. On the one hand, current
and proposed drug laws that apply to the public also apply to re-
searchers. On the other hand, multi-billion dollar projects, like
Europe's Human Brain Project, the US's BRAIN Initiative, and the
World Health Organization (WHO)'s Mental Health Action Plan 2013–
2020, incentivize neuroscience research aimed at tackling the globalhttp://dx.doi.org/10.1016/j.ebiom.2015.07.016
2352-3964/© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NChealth epidemic of mental illness. Affecting over 400 million people
worldwide, mental illness is the second-leading cause of otherwise
healthy days lost to disability. With ever-increasing incidence rates of
major depressive disorder, anxiety disorders, schizophrenia, autism
spectrum disorders, and dementia, neuropsychiatric disorders are
poised to become the most economically burdensome diseases on the
planet within a decade.
Existing research programs are lagging behind the growing need,
with many pharmaceutical companies divesting from neuropsychiatric
research, leaving a drought in the drug development pipeline. Despite
current obstacles in psychiatric research, though, promising results are
arising from early preclinical testing of psychoactive substances.
MDMA has been shown effective in the treatment of post-traumatic
stress disorder and social anxiety. LSD and psilocybin can assist in alco-
hol addiction rehabilitation. Cannabis, illegal in many countries, has
been used to treat an array of disorders, including multiple sclerosis,
chronic pain, nausea, and epilepsy. Notably, legalization of marijuana
formedical use in someUS states has not affected overall rates of canna-
bis use among adolescents. Expanding drug laws, without speciﬁc con-
cessions to scientists, will only reinforce existing barriers to research
and prevent potentially life-changing therapies from being realized.
In July 2013, instead of a blanket ban on NPSs, New Zealand
enacted a different approach: testing. Any new molecule that is
chemically related to or intended to have similar physiological ef-
fects as another psychoactive compound is subject to the same rigor-
ous testing as other pharmaceuticals before being publically
available, with manufacturers and experimenters being strictly reg-
ulated. Under these policies, NPS availability has dropped 75%. To
date, no NPS has been licensed in New Zealand, but the pragmatic,
scientiﬁc approach of the law seems admirable. Can we outlaw or re-
strict access to a drug for having no medical use and for affecting the
user's mental functioning or emotional state without explicitly
researching those concerns?
The Psychoactive Substances Bill inadvertently exposes numer-
ous paradoxes and contradictions in the way governments, society,
and individuals think about drugs. Policymakers would need to re-
evaluate why amphetamines can be used to treat Attention Deﬁcit-
Hyperactivity Disorder while methamphetamine is illegal. Or why
the cathinone buproprion can be prescribed for major depressive
disorder but its analog, mephedrone, is banned. And why trypt-
amines are available for treatment of migraines while the related
LSD and psilocybin are Schedule I drugs. Explicit clarity in legislation
would be required in exempting current psychoactive substances,
including some opioid analgesics with both high therapeutic value
and abuse potential, along with alcohol and tobacco, which kill 2.5
and 6 million people per year, respectively.-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
614 EditorialA second reading of the Psychoactive Substances Bill began on June
30, 2015. Skepticswarned “of a lack of research underpinning policy de-
velopment” that had policymakers operating “effectively blind.”While
new legislation to address developing concerns on psychoactive
substances is mandatory, so must be the careful measurement of their
harms and potential beneﬁts. The overwhelming burden of mental
illness demands and deserves a thoughtful, non-reactionary approachin managing the molecules that could be tomorrow's psychiatric
medicines.
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